PH12020550683A1 - Novel bradykinin b2 receptor antagonists - Google Patents
Novel bradykinin b2 receptor antagonistsInfo
- Publication number
- PH12020550683A1 PH12020550683A1 PH12020550683A PH12020550683A PH12020550683A1 PH 12020550683 A1 PH12020550683 A1 PH 12020550683A1 PH 12020550683 A PH12020550683 A PH 12020550683A PH 12020550683 A PH12020550683 A PH 12020550683A PH 12020550683 A1 PH12020550683 A1 PH 12020550683A1
- Authority
- PH
- Philippines
- Prior art keywords
- receptor antagonists
- compound
- bradykinin
- novel bradykinin
- novel
- Prior art date
Links
- 229940123765 Bradykinin B2 receptor antagonist Drugs 0.000 title 1
- 239000003359 bradykinin B2 receptor antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 101800004538 Bradykinin Proteins 0.000 abstract 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 2
- 102100035792 Kininogen-1 Human genes 0.000 abstract 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17203675 | 2017-11-24 | ||
| PCT/EP2018/082338 WO2019101906A1 (en) | 2017-11-24 | 2018-11-23 | Novel bradykinin b2 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12020550683A1 true PH12020550683A1 (en) | 2021-03-15 |
Family
ID=60473364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12020550683A PH12020550683A1 (en) | 2017-11-24 | 2020-05-21 | Novel bradykinin b2 receptor antagonists |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10836748B2 (enExample) |
| EP (2) | EP3998259A1 (enExample) |
| JP (2) | JP7164619B2 (enExample) |
| KR (1) | KR102413321B1 (enExample) |
| CN (1) | CN111433196B (enExample) |
| AR (1) | AR113839A1 (enExample) |
| AU (1) | AU2018371186B2 (enExample) |
| BR (1) | BR112020010298A2 (enExample) |
| CA (1) | CA3082948A1 (enExample) |
| CY (1) | CY1125348T1 (enExample) |
| DK (1) | DK3713928T3 (enExample) |
| EA (1) | EA202091256A1 (enExample) |
| ES (1) | ES2908409T3 (enExample) |
| HR (1) | HRP20220429T1 (enExample) |
| HU (1) | HUE058217T2 (enExample) |
| IL (1) | IL274883B2 (enExample) |
| LT (1) | LT3713928T (enExample) |
| MA (1) | MA50804B1 (enExample) |
| MX (1) | MX2020005287A (enExample) |
| PH (1) | PH12020550683A1 (enExample) |
| PL (1) | PL3713928T3 (enExample) |
| PT (1) | PT3713928T (enExample) |
| RS (1) | RS63087B1 (enExample) |
| SG (1) | SG11202004653TA (enExample) |
| SI (1) | SI3713928T1 (enExample) |
| SM (1) | SMT202200154T1 (enExample) |
| TW (1) | TWI768156B (enExample) |
| UY (1) | UY37981A (enExample) |
| WO (1) | WO2019101906A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3713928T (lt) | 2017-11-24 | 2022-05-10 | Pharvaris Netherlands B.V. | Nauji bradikinino b2 receptoriaus antagonistai |
| UY38707A (es) * | 2019-05-23 | 2020-12-31 | Pharvaris Gmbh | Nuevos antagonistas cíclicos del receptor b2 de bradiquinina |
| AR118982A1 (es) * | 2019-05-23 | 2021-11-17 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
| WO2022101395A1 (en) | 2020-11-12 | 2022-05-19 | Pharvaris Gmbh | Prophylaxis and treatment of angioedema |
| MX2024001711A (es) * | 2021-08-05 | 2024-03-05 | Pharvaris Gmbh | Composición lípidica para la administración oral de antagonistas del receptor de bradicinina b2. |
| EP4380929A1 (en) | 2021-08-05 | 2024-06-12 | Pharvaris GmbH | Solid form of a bradykinin b2-receptor antagonist |
| IL315699A (en) | 2022-03-25 | 2024-11-01 | Pharvaris Gmbh | A solid composition comprising dissolved bradykinin B2 receptor antagonists |
| TW202345810A (zh) | 2022-03-25 | 2023-12-01 | 瑞士商帕法瑞斯有限責任公司 | 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物 |
| EP4499100A1 (en) | 2022-03-25 | 2025-02-05 | Pharvaris GmbH | Therapeutic uses of bradykinin b2-receptor antagonists |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU680870B2 (en) | 1993-04-28 | 1997-08-14 | Astellas Pharma Inc. | New heterocyclic compounds |
| KR970707098A (ko) | 1994-10-27 | 1997-12-01 | 후지야마 아키라 | 브라디키닌 길항제로서 피리도피리미돈, 퀴놀린 및 융합된 N-헤테로사이클(Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists) |
| FR2737892B1 (fr) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique |
| GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| DE19609827A1 (de) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
| DE19610784A1 (de) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| DE19612067A1 (de) | 1996-03-27 | 1997-10-02 | Hoechst Ag | Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von chronisch fibrogenetischen Lebererkrankungen und akuten Lebererkrankungen |
| AUPN952696A0 (en) * | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| JP2002517461A (ja) | 1998-06-08 | 2002-06-18 | アドバンスド メディスン インコーポレーテッド | ブラジキニンアンタゴニスト |
| WO2000023439A1 (en) | 1998-10-21 | 2000-04-27 | Fujisawa Pharmaceutical Co., Ltd. | Vitreous form of known bradykinin antagonist |
| FR2790260B1 (fr) | 1999-02-26 | 2001-05-04 | Fournier Ind & Sante | Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique |
| GB9913079D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| AU2001229580A1 (en) | 2000-01-18 | 2001-08-14 | Nuerogen Corporation | Substituted imidazoles as selective modulators of bradykinin b2 receptors |
| CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| CA2481855A1 (en) | 2002-04-10 | 2003-10-23 | Ortho-Mcneil Pharmaceutical, Inc. | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators |
| ITMI20021247A1 (it) | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
| ITMI20041963A1 (it) | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
| EP1741444A1 (en) | 2005-07-05 | 2007-01-10 | Jerini AG | Kinin antagonists for treating bladder dysfunction |
| TWI407960B (zh) * | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| AR073304A1 (es) * | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
| JP2016514141A (ja) | 2013-03-14 | 2016-05-19 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | Ｂ２−ブラジキニン受容体媒介の血管浮腫の治療方法 |
| LT3713928T (lt) | 2017-11-24 | 2022-05-10 | Pharvaris Netherlands B.V. | Nauji bradikinino b2 receptoriaus antagonistai |
-
2018
- 2018-11-23 LT LTEPPCT/EP2018/082338T patent/LT3713928T/lt unknown
- 2018-11-23 EA EA202091256A patent/EA202091256A1/ru unknown
- 2018-11-23 WO PCT/EP2018/082338 patent/WO2019101906A1/en not_active Ceased
- 2018-11-23 PL PL18818992T patent/PL3713928T3/pl unknown
- 2018-11-23 ES ES18818992T patent/ES2908409T3/es active Active
- 2018-11-23 EP EP21213719.4A patent/EP3998259A1/en active Pending
- 2018-11-23 CN CN201880076162.XA patent/CN111433196B/zh active Active
- 2018-11-23 PT PT188189922T patent/PT3713928T/pt unknown
- 2018-11-23 RS RS20220335A patent/RS63087B1/sr unknown
- 2018-11-23 EP EP18818992.2A patent/EP3713928B1/en active Active
- 2018-11-23 MX MX2020005287A patent/MX2020005287A/es unknown
- 2018-11-23 AU AU2018371186A patent/AU2018371186B2/en active Active
- 2018-11-23 SI SI201830628T patent/SI3713928T1/sl unknown
- 2018-11-23 DK DK18818992.2T patent/DK3713928T3/da active
- 2018-11-23 SM SM20220154T patent/SMT202200154T1/it unknown
- 2018-11-23 SG SG11202004653TA patent/SG11202004653TA/en unknown
- 2018-11-23 KR KR1020207017972A patent/KR102413321B1/ko active Active
- 2018-11-23 AR ARP180103444A patent/AR113839A1/es unknown
- 2018-11-23 JP JP2020545875A patent/JP7164619B2/ja active Active
- 2018-11-23 CA CA3082948A patent/CA3082948A1/en active Pending
- 2018-11-23 UY UY0001037981A patent/UY37981A/es active IP Right Grant
- 2018-11-23 TW TW107141872A patent/TWI768156B/zh active
- 2018-11-23 MA MA50804A patent/MA50804B1/fr unknown
- 2018-11-23 BR BR112020010298-9A patent/BR112020010298A2/pt active IP Right Grant
- 2018-11-23 IL IL274883A patent/IL274883B2/en unknown
- 2018-11-23 HU HUE18818992A patent/HUE058217T2/hu unknown
- 2018-11-23 HR HRP20220429TT patent/HRP20220429T1/hr unknown
-
2020
- 2020-04-28 US US16/861,131 patent/US10836748B2/en active Active
- 2020-05-21 PH PH12020550683A patent/PH12020550683A1/en unknown
- 2020-09-25 US US17/033,347 patent/US11261173B2/en active Active
-
2022
- 2022-01-18 US US17/578,161 patent/US11820756B2/en active Active
- 2022-04-11 CY CY20221100272T patent/CY1125348T1/el unknown
- 2022-10-20 JP JP2022168473A patent/JP2023002701A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550683A1 (en) | Novel bradykinin b2 receptor antagonists | |
| NZ747259A (en) | Soluble c5ar antagonists | |
| PH12019501937A1 (en) | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | |
| EP4248968A3 (en) | Tlr7/8 antagonists and uses thereof | |
| MX389592B (es) | Moduladores alostericos positivos del receptor m1 muscarinico | |
| EA202091262A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
| MX2021000093A (es) | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos. | |
| PH12019500731A1 (en) | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors | |
| ZA202001780B (en) | Bezimidazole derivatives as adenosine receptor antagonists | |
| PH12017501424B1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| MX2021014287A (es) | Nuevos antagonistas ciclicos del receptor b2 de bradiquinina. | |
| PH12021550705A1 (en) | Stable semaglutide compositions and uses thereof | |
| MY199762A (en) | Moisturizing topical preparation | |
| MX2020005483A (es) | Antagonistas de ildr2 y combinaciones de los mismos. | |
| EA201890534A1 (ru) | Новые аннелированные феноксиацетамиды | |
| MX2018002006A (es) | Benzamidas apareadas novedosas. | |
| MX2015011536A (es) | Nuevos antagonistas de receptores trpa1 de sulfamidas. | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| PH12020551341A1 (en) | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof | |
| ZA202001295B (en) | Thiazolopyridine derivatives as adenosine receptor antagonists | |
| NZ763341A (en) | Polycyclic amides as muscarinic m1 receptor positive allosteric modulators | |
| NZ764004A (en) | Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators | |
| UY38706A (es) | Antagonistas cíclicos del receptor b2 de bradiquinina | |
| MX2019007786A (es) | Compuestos sustituidos de guanidina. |